AUTHOR INDEX

(P = Proceedings)

AARTS, L.P.H.J. *see* KNIBBE, C.A.J.
ABDELMAWLA, A.H., LANGLEY, R.W., SZABADI, E. & BRADSHAW, C.M. Platelet CD62 expression and $PDGF_{AB}$ secretion in patients undergoing PTCA and treatment with abciximab: 581
ABDUL-MANAP R. *see* ROSTAMI-HODJEGAN, A.
ABENHAIM, L. *see* VAN STAAR, T.P.
ABERNETHY, D.R., WESCHE, D.L., BARBEY, J.T., OHRT, C., MOHANTY, S., PEZZULLO, J.C. & SCHUSTER, B.G. Responsiveness of human varicose saphenous veins to vasoactive agents: 231
ADWANI, S.H. *see* WARING, W.S.
AGOSTONI, P. *see* GUAZZI, M.
AHMADI-ABHARI, S.A. *see* AKHONDZADEH, S.
AKHONDZADEH, S., AHMADI-ABHARI, S.A., ASSADI, S.M. & SHABESTARI, O.L. Double-blind randomized control trial of baclofen *vs* clonidine in the treatment of opiate withdrawl: 364P
ALBUNNI, M. *see* PADRINI, R.
ALPÉROVITCH, A. *see* FOURRIER, A.
ALTAVILLA G. *see* SCORDO, M.G.
ALTMAN, C. *see* MARCELLIN, P.
ANDERSSON, N., KÄLLÉN, A. & THORSSON, L. A randomized controlled assessment of the effects of different dosing regimens of budesonide on the HPA-axis in healthy subjects: 325
ANDREASEN, F. *see* BARAT, I.
ANDRIES, D. *see* GRAFF, J.
ARCORACI, V., MAZAGLIA, G.P., CUCCINOTTA, G., NICOLETTI, G., CICCIÙ, D. & CAPUTI A.P. Antibiotic prescriptions in oral cavity infections: a pharmacoepidemiological study among Italian dentists: 371P
ARNAUD, P. *see* BOULTON, D.W.
ASADA, A. *see* ODA, Y.
ASSADI, S.M. *see* AKHONDZADEH, S.
ASTRUP, A. *see* VAN BAAK, M.A.
AUTRET-LECA, E. *see* JONVILLE-BÉRA, A.-P.
AYIS, A.S. *see* REILLY, J.G.
AYMARD, G. *see* MOULY, S.
AZIE, N.E. *see* FLEISHAKER, J.C.

BACK, D. *see* HENNESSEY, M.
BACK, D.J. *see* CLARKE, S.M.
BACK, D.J. *see* JONES, K.
BACK, D.J., KHOO, S.H., GIBBONS, S.E. & MERRY, C. The role of therapeutic drug monitoring in treatment of HIV infection: 301
BAKER, R.C. *see* DALEY-YATES, P.T.
BALL, D. *see* DEWIT, O.
BARAT, I., ANDREASEN, F. & DAMSGAARD, E.M.S. A 6-months large-scale study into the safety of tamsulosin: 613
BARBEILLON, F. *see* JONVILLE-BÉRA, A.-P.
BARBEY, J.T. *see* ABERNETHY, D.R.
BARCLAY, M.L. *see* BEGG, E.J.
BARCLAY, M.L. *see* MARTIN, J.H.
BARRY, M. *see* HENNESSEY, M.
BARRY, M. *see* RYAN, M. and HENNESSEY, M.
BARRY, M.G. *see* CLARKE, S.M.
BARUGOLA NATAF, M. *see* PAGEAUX, G.P.
BASSUS, S. *see* GRAFF, J.
BATEMAN, D.N. *see* WARING, W.S.
BATTY, K.T. *see* BINH, T.Q.
BEAL, J.B. *see* GROSS, A.S.
BÉGAUD, B. *see* FOURRIER, A.
BEGG, E.J. *see* MARTIN, J.H.
BEGG, E.J., BARCLAY, M.L. & KIRKPATRICK, C.J.M. Drug interactions and infectious diseases: 491
BEGG, E.J., ROBSON, R.A., GARDINER, S.J., HUDSON, L.J., REECE, P.A., OLSON, S.C., POSVAR, E.L. & SEDMAN, A.J. Quinapril and its metabolite quinaprilat in human milk: 164
BEGG, E.J., ROBSON, R.A., GARDINER, S.J., HUDSON, L.J., REECE, P.A., OLSON, S.C., POSVAR, E.L. & SEDMAN, A.J. Quinapril and its metabolite quinaprilat in human milk: 478
BEIJNEN, J.H. *see* DE MAAT, M.M.R.
BEIJNEN, J.H. *see* HUITEMA, A.D.R.
BEIJNEN, J.H. *see* KOKS, C.H.W.
BEIJNEN, J.H. *see* VELDKAMP, A.I.
BELGER, H. *see* BRODDE, O.-E.
BELL, D.J.A. *see* FLEISHAKER, J.C.
BELLOCCO, G. *see* SCORDO, M.G.
BENJAMIN, N. *see* KAVANAGH, S.L.
BENNINGA, M. *see* WIERSMA, H.E.
BENÖHR, P. *see* LUIPPOLD, G.
BENOWITZ, N.L. & JACOB, P. Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol: 53
BERGMANN, J.F. *see* MOULY, S.
BIDAULT, R. *see* MARCELLIN, P.
BIGONI, R., CALO, G., GUERRINI, R., STRUPISH, J.W., ROWBOTHAM, D.J. & LAMBERT, D.G. Effects of nociceptin and endomorphin 1 on the electrically stimulated human vas deferens: 355
BINH, T.Q., ILETT, K.F., BATTY, K.T., DAVS, T.M.E., HUNG, N.C., POWELL, S.M., THU, L.T.A., THIEN, H.V., PHUÖNG, H.L. & PHUONG, V.D.B. Thioguanine in children with acute lymphoblastic leukaemia: influence of food on parent drug pharmacokinetics and 6-thioguanine nucleotide concentrations: 539
BIRKETT, D. *see* MCMANUS, P.
BISWAS, N.R., JINDAL, S., SIDDIQUEI, M.M. & MAINI, R. Evaluation of a pharmacokinetic interaction between remacemide hydrochloride and phenobarbitone in healthy males: 267
BLAKEY, G.E. *see* HOOPER, W.D.
BLIN, O. *see* PAGEAUX, G.P.
BOIGE, V. *see* MARCELLIN, P.
BONHAM, J. *see* JOHNSON, T.N.
BONNER, C.J. *see* ROBERTS, M.S.
BOUHOURS, P. *see* PAGEAUX, G.P.
BOULTON, D.W., ARNAUD, P. & DEVANE, C.L. A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio: 350
BOVEN, E. *see* VERSCHRAAGEN, M.
BRADSHAW, C.M. *see* ABDELMAWLA, A.H.
BRAMBILLA, R. *see* GUAZZI, M.
BREKELMANS, G.J.F. *see* EDELBROEK, P.M.
BRESSEL, H.U. *see* MICHEL, M.C.
BRODDE, O.-E. *see* SCHMUCK, S.
BRODDE, O.-E., BELGER, H., TELLKAMP, R., BÜSCHER, R., EILMES, K.J., RADKE, J. & DHEIN, S. Functional role of the Gly389Arg polymorphism of the β_2-adrenoreceptor: *in vivo* studies in healthy volunteers: 367P
BROOKS, G.E. *see* ROBERTS, M.S.
BROUWER, K.L.R. *see* CREWS, K.R.
BRUBAKER, J.A. *see* WALLE, T.
BRUNNER, F., HOFFMANN, C. & SCHULLER-PETROVIC, S. New insights into drug metabolism and toxicology, 219
BRYNNE, L., MCNAY, J.L., SCHAEFER, H.G., SWEDBERG, K., WILTSE, C.G. & KARLSSON, M.O. Effect of dexmedetomidine, an α-2 agonist, on human pupillary reflexes during general anaesthesia: 35
BUCK, H., ELLIS, S., GODFREY C. &

© 2001 Blackwell Science Ltd

MORICE A. Pharmacokinetic evaluation based on plasma budesonide levels: comparison of pulmonary delivery for two dry powder inhalers: 373P
BURGER, D.M. *see* KOKS, C.H.W.
BURKE, M.T. *see* FLEISHAKER, J.C.
BÜSCHER, R. *see* SCHMUCK, S. and BRODDE, O.-E.
BUTLER, R. *see* SHEHAB, A.M.A.
BUTTER, J.J. *see* WIERSMA, H.E.

CAI, W.M., CHEN, B., LING, S.S. & ZHANG, Y.D. Systemic bioavailability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulation: 107
CALO, G. *see* BIGONI, R.
CALOGERO, G.F., SERVELLO, M.M., FAVA, G., Di BERNARDO, N., CAMINITI, F., FRAGOMENO, C., MINUTOLI L. & CAPUTI, A.P. Adverse drug events (ADEs) in emergency departments (ED) around the Strait or Messina: 377P
CAMINITI, F. *see* CALOGERO, G.F.
CAPUTI A.P. *see* ARCORACI, V.
CAPUTI, A.P. *see* CALOGERO, G.F.
CAREL, B.J. *see* FLEISHAKER, J.C.
CARIGNAN, G. *see* KHALIQ, Y.
CASPER, E.S. *see* TANSWELL, P.
CASTELNAU, C. *see* MARCELLIN, P.
CAULFIELD, M. *see* WILSON, S.L.
CAULFIELD, M.J. Genes for common diseases: 1
CAULIN, C. *see* MOULY, S.
CHA, I.-J. *see* YOON, Y.-R.
CHADWICK, D. *see* OWEN, A.
CHAKRAPANI, A. *see* JOHNSON, T.N.
CHAN, E., LEE, H.S. & HUE, S.S. Increased oral ganciclovir bioavailablility in HIV-infected patients with diarrhoea and wasting syndrome—a population pharmacokinetic study: 565
CHAN, R. *see* MCGETTIGAN, P.
CHARLETT, A., OXLADE, N., WELLER, C., DOBBS, S.M., DOBBS, R.J. & PETERSON, D.W. Relationship of *Helicobacter pylori* serum antibody profile to deterioration in psychomotor performance and cognitive processing in idiopathic parkinsonism: 388P
CHEN, B. *see* CAI, W.M.
CHEN, C. *see* MARCELLIN, P.
CHEN, J. *see* SONG, E.
CHIBA, K. *see* KUBOTA, T.
CHOSIDOW, O. *see* LEBRUN-VIGNES, B.
CHOWIENCZYK, P.J. *see* WALKER, H.A.
CHRYSTYN, H. *Research methods in human respiratory pharmacology edited by Professor A.H. Morice*, 289
CICCIÙ, D. *see* ARCORACI, V.
CLARKE, S. *see* HENNESSEY, M.
CLARKE, S.M., MULCAHY, F.M., TJIA, J., REYNOLDS, H.E., GIBBONS, S.E., BARRY, M.G. & BACK, D.J. Anti-TNF agents for rheumatoid arthritis: 213
CLEOPHAS, T.J. & VAN MARUM, R. Efficacy and safety of second generation dihydropyridine calcium channel blockers in heart failure, a meta-analysis, 506P
CLEOPHAS, T.J., VAN OUWERKERK, B.M., VAN DER MEULEN, J., ZWINDERMAN, A.H. & VAN MARUM, R. Hypertensive patients with diabetes mellitus type II inadequately controlled by angiotensin converting enzyme inhibitors: is the combination with long-acting calcium channel blockers more effective than with β-adrenoceptor blockers, 493P
COHEN, A.F. *see* DE VISSER, S.J.
COHEN, A.F. *see* DE VISSER, S.J.
COLLIER, D.J. *see* WILSON, S.L.
COLLINS, P. & WILLIAMS, G. *Genes for common diseases edited by Prof. M.J. Caulfield*, 13
COOPER, C. *see* KHALIQ, Y.
COOPER, C. *see* VAN STAAR, T.P.
CORBRION ARCHER, V. *see* LEBRUN-VIGNES, B.
CRANSBERG, K. *see* VAN ROSSUM, L.K.
CREWS, K.R., MURTHY, B.P., HUSSEY, E.K., PASSANNANTE, A.N., PALMER, J.L., MAIXNER, W. & BROUWER, K.L.R. Lack of effect of ondansetron on the pharmacokinetics and analgesic effects of morphine and metabolites after single-dose morphine administration in healthy volunteers: 309
CROMMENTUYN, K.H.W. *see* KOKS, C.H.W.
CUCCINOTTA, G. *see* ARCORACI, V.
CUGOLA, M. *see* ZIVIANI, L.
CULLBERG, M., ERIKSSON, U.G., LARSSON, M. & KARLSSON, M.O. Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patient undergoing high-dose chemotherapy: 71

DA ROS, L. *see* ZIVIANI, L.
DAHL, M.L. *see* SCORDO, M.G.
DAHLQVIST, R. *see* HÄGG, S.
DALEY-YATES, P.T. & BAKER, R.C. Effect of α_1-acid glycoprotein on the intracellular accumulation of the protease inhibitors saquinavir, ritonavir and indinavir *in vitro*: 103
DALEY-YATES, P.T., PRICE, A.C., SISSON, J.R., PEREIRA, A. & DALLOW, N. Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man: 400
DALHOFF, K. *see* SCHMIDT, L.E.
DALLOW, N. *see* DALEY-YATES, P.T.
DAMSGAARD, E.M.S. *see* BARAT, I.
DANHOF, M. *see* KNIBBE, C.A.J.
DAVID, O.J. & JOHNSON, A. A practical tool for estimating cyclosporin blood concentrations at 2 h post-dose (C2) in stable renal transplant patients: 387P
DAVS, T.M.E. *see* BINH, T.Q.
DE BOER, A. *see* DE MAAT, M.M.R.
DE BOER, A. *see* SCHILLEVOORT, I.
DE BOER, A. *see* TEEUWISSE, A.K.
DE BOER, A. *see* VAN DE VIJVER, D.A.M.C.
DE BONY, F. *see* MARCELLIN, P.
DE HOON, J.N.J.M., TROOST, J., VAN BORTEL, L.M.A.B. & STRUIJKER-BOUDIER, H.A.J. Selective 5-$HT_{1B/1D}$-receptor agonist-induced peripheral vascular changes in migraine patients, 501P
DE KLERK, S. *see* MULDER, W.M.C.
DE LEIJ, L.F.M.H. *see* TAMMINGA, W.J.
DE LOOZE, F.J. *see* ROBERTS, M.S.
DE MAAT, M.M.R., FRANKFORT, S.V., MATHOT, R.A.A., MULDER, J.W., MEENHORST, P.L., VAN GORP, E.C.M., BEIJNEN, J.H., DE BOER, A. & HOETELMANS, R.M.W. Discrepancies between drug notations in medical records and public pharmacy records in a HIV-1 infected population: a potential for drug-drug interactions, 497P
DE METZ, M. *see* VAN KRAAIJ, D.J.W.
DE RIJKE, Y.B. *see* VAN ROSSUM, L.K.
DE VISSER, S.J., VAN DER POST, J., PIETERS, M.S.M., COHEN, A.F., VAN GERVEN & J.M.A. Biomarkers for the effects of antipsychotic drugs in healthy volunteers: 119
DE VISSER, S.J., VAN GERVEN, J.M.A., SCHOEMAKER, R.C. & COHEN, A.F. Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects: 423
DE VRIES, C.S. *see* OLESEN, C.
DE ZEEUW, R.A. *see* TAMMINGA, W.J.
DEBETS, R.M.Chr. *see* EDELBROEK, P.M.
DECKER, N. *see* FOURRIER, A.
DEJONGH, J. *see* KNIBBE, C.A.J.
DEL MAR, C.B. *see* ROBERTS, M.S.
DERIJKS, L.J.J., ENGELS, L.G.J.B., HOOYMANS, P.M. & LOHMAN, J.J.H.M. Pharmacokinetics of 6-mercaptopurine and azathioprine in patients with inflammatory bowel disease, 509P

DERKX, F. *see* VAN ROSSUM, L.K.
DESMET, M. *see* VAN BAAK, M.A.
DEVANE, C.L. *see* BOULTON, D.W.
DEWIT, O., BALL, D., HIRST, P.H., NEWMAN, S.P., WRAY, H., RITCHIE S. & VOUSDEN M. Scintigraphic assessment of nasal deposition and clearance of an aqueous nasal spray administered to healthy volunteers whilst experiencing a common cold: 374P
DHEIN, S. *see* SCHMUCK, S. and BRODDE, O.-E.
DI BERNARDO, N. *see* CALOGERO, G.F.
DIQUET, B. *see* LEBRUN-VIGNES, B.
DIVGI, C.R. *see* TANSWELL, P.
DOBBS, R.J. *see* CHARLETT, A.
DOBBS, S.M. *see* CHARLETT, A.
DROOGLEEVER-FORTUYN, H. *see* VAN DEN BERG, E.J.
DUDLEY, J. *see* MCMANUS, P.
DUGUID, M. *see* SHENFIELD, G.M.

EADIE, M.J. *see* HOOPER, W.D.
EBEJER, M.J. *see* FENECH, A.G.
ECCLES, R. *see* LEE, P.C.L.
EDELBROEK, P.M., VERMEIJ, T.A.C., BREKELMANS, G.J.F., DEBETS, R.M.Chr., GEESINK, H.H. & RADEMAKER, M.V. Therapeutic drug monitoring of antiepileptic drugs in blood spots dried on filter paper, 494P
EDSBÄCKER, S. *see* PETERSEN, H.
EILMES, K.J. *see* SCHMUCK, S. and BRODDE, O.-E.
EL ERAKY, H. & THOMAS S.H.L. Gender differences in the ECG effects of quinidine: 376P
EL ERAKY, H. & THOMAS S.H.L. Quinidine does not increase QT dispersion in healthy volunteers: 376P
EL ERAKY, H. & THOMAS, S.H.L. Gender does not affect single-dose pharmacokinetics of quinidine: 366P
ELLIS, S. *see* BUCK, H.
ELLUL-MICALLEF, R. *see* FENECH, A.G.
ELSNER, M. *see* GRAFF, J.
ENGELS, L.G.J.B. *see* DERIJKS, L.J.J.
ERIKSSON, U.G. *see* CULLBERG, M.

FAVA, G. *see* CALOGERO, G.F.
FEDER, G. *see* WILSON, S.L.
FEELY, J. *see* HENNESSEY, M.
Feely, J. *see* Mcgettigan, P.
FEELY, J. *see* WILLIAMS, D. and MAHMUD, A.
Feldman, A.M. *see* Soran, O.
FELICE, A.E. *see* FENECH, A.G.
FENECH, A.G., WHEATLEY, A.P., EBEJER, M.J., FELICE, A.E., ELLUL-MICALLEF, R. & HALL, I.P. Mutation screening of the human muscarinic M_2 and M_3 receptor genes in normal and asthmatic individuals: 390P
FERRARI, M. *see* PADRINI, R.
FERRIER, I.N. *see* REILLY, J.G.
FINN, R.D. *see* TANSWELL, P.
FLEISHAKER, J.C., RYAN, K.K., JANSAT, J.M., CAREL, B.J., BELL, D.J.A., BURKE, M.T. & AZIE, N.E. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent, in humans: 437
FLOCKHART, D.A. *see* SHIN, J.-G.
FORD, G.A. A textbook of clinical pharmacology: 491
FOURRIER, A., BÉGAUD, B., ALPÉROVITCH, A., VERDIER-TAILLEFER, M.-H., TOUZE, E., DECKER, N. & IMBS, J.L. Hepatitis B vaccine and first episodes of central nervous system demyelinating disorders: a comparison between reported and expected number of cases: 485
FOWLER, S.J. & LIPWORTH, B.J. Pharmacokinetics and systemic β_2-adrenoceptor-mediated responses to inhaled salbutamol: 359
FRAGOMENO, C. *see* CALOGERO, G.F.
FRANKFORT, S.V. *see* DE MAAT, M.M.R.
FRANZ, N. *see* GRAFF, J.
FRÖLICH, J.C. *see* SCHNURRER, J.U.
FRYER, J. *see* MCGETTIGAN, P.
FUNAE, Y. *see* ODA, Y.

GALLICANO, K. *see* KHALIQ, Y.
GARDINER, S.J. *see* BEGG, E.J.
GARIN-CHESA, P. *see* TANSWELL, P.
GARRET, C. *see* MARCELLIN, P.
GEESINK, H.H. *see* EDELBROEK, P.M.
GIBBONS, S.E. *see* BACK, D.J.
GIBBONS, S.E. *see* CLARKE, S.M.
GLASZIOU, P.P. *see* ROBERTS, M.S.
GLOVER, D.R. *see* POWELL, J.
GODFREY C. *see* BUCK, H.
GOEPEL, M. *see* MICHEL, M.C.
GOLDEN, J. *see* MCGETTIGAN, P.
GOOD, A.M. *see* WARING, W.S.
GOTTESDIENER, K. M. *see* VAN BAAK, M.A.
GRAFF, J., ANDRIES, D., ELSNER, M., WESTRUP, D., BASSUS, S., FRANZ, N., KLINKHARDT, U. & HARDER, S. Population pharmacokinetics of carbamazepine in Singapore epileptic patients: 575
GREEN, C.F., MOTTRAM, D.R., ROWE, P.H. & PIRMOHAMED, M. Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time () in healthy subjects and patients with coronary artery disease: 81
GREIFF, L. *see* PETERSEN, H.
GROSS, A.S., MCLACHLAN, A.J., MINNS, I., BEAL, J.B. & TETT, S.E. Oral bioavailability of dihydroartemisinin in Vietnamese volunteers and in patients with falciparum malaria: 545
GUAZZI, M., BRAMBILLA, R., AGOSTONI, P. & GUAZZI, M.D. Influence of ACE-inhibition on saltmediated worsening of pulmonary gas exchange in heart failure: 482
GUAZZI, M.D. *see* GUAZZI, M.
GUERRINI, R. *see* BIGONI, R.
GUSELLA, M. *see* PADRINI, R.

HACKETT, D. *see* MEONI, P.
HÄGG, S., SPIGSET, O. & DAHLQVIST, R. Influence of gender and oral contraceptives on and activity in healthy volunteers: 172
HALL, I.P. *see* FENECH, A.G.
HALUSHKA, P.V. *see* WALLE, T.
HAMAOKA, N. *see* ODA, Y.
HANNA, R. *see* SORAN, O.
HARDER, S. *see* GRAFF, J.
HASE, I. *see* ODA, Y.
HAUDIQUET, V. *see* MEONI, P.
HAUSHEER, F.H. *see* VERSCHRAAGEN, M.
HEERDINK, E.R. *see* MEIJER, W.E.E.
HEEREY, A. *see* RYAN, M.
HENNESSEY, M., BARRY, M., KAVANAGH, P., KELLEHER, D., BACK, D. & FEELY, J. A role for P-glycoprotein expression and function in drug interactions with St John's Wort: 389P
HENNESSEY, M., CLARKE, S., MULCAHY, F., TJIA, J., MAHER, B., BACK, D. & BARRY M. Intracellular indinavir pharmacokinetics in HIV-positive patients: 385P
HIROI, T. *see* ODA, Y.
HIRST, P.H. *see* DEWIT, O.
HOETELMANS, R.M.W. *see* DE MAAT, M.M.R.
HOETELMANS, R.M.W. *see* KOKS, C.H.W.
HOETELMANS, R.M.W. *see* VELDKAMP, A.I.
HOFFMANN, C. *see* BRUNNER, F.
HOGGARD, P.G. *see* JONES, K.
HOOPER, W.D., EADIE, M.J., BLAKEY, G.E., LOCKTON, J.A. & MANUN'EBO, M. Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation: 249
HOOYMANS, P.M. *see* DERIJKS, L.J.J.
HOOYMANS, P.M. *see* VAN DER KUY, P-H.M.
HUDSON, L.J. *see* BEGG, E.J.
HUE, S.S. *see* CHAN, E.

HUGHES, A.D. *see* WIMALASUNDERA, R.
HUITEMA, A.D.R., MATHÔT, R.A.A., TIBBEN, M.M., SCHELLENS, J.H.M., RODENHUIS, S. & BEIJNEN, J.H. Trans-3′-hydroxycontinine: disposition kinetics, effects, and plasma levels during cigarette smoking., 61
HUL, G. *see* VAN BAAK, M.A.
HULL, J.D. *see* LEE, P.C.L.
HULTING, A.-L. *see* MELKERSSON, K.I.
HUNG, N.C. *see* BINH, T.Q.
HUSSEY, E.K. *see* CREWS, K.R.
HYLAND, R., ROE, E.G.H., JONES, B.C. & SMITH, D.A. Assessment of forearm vasodilator responses to acetylcholine and albuterol by strain gauge plethysmography: reproducibility and influence of strain gauge placement: 239

IAVARONE, L.E. *see* ZIVIANI, L.
ILETT, K.F. *see* BINH, T.Q.
IMAOKA, S. *see* ODA, Y.
IMBS, J.L. *see* FOURRIER, A.
ISHIZAKI, T. *see* ODA, Y.

JACKSON, G. *see* WALKER, H.A.
JACOB, P. *see* BENOWITZ, N.L.
JANSAT, J.M. *see* FLEISHAKER, J.C.
JANSEN, P.A.F. *see* SCHILLEVOORT, I.
JANSEN, P.A.F. *see* VAN DE VIJVER, D.A.M.C.
JAWAD, M.S.M. *see* LEE, P.C.L.
JINDAL, S. *see* BISWAS, N.R.
JOHNSON, A. *see* DAVID, O.J.
JOHNSON, T.N., ROSTAMI-HODJEGAN, A., CHAKRAPANI, A. & TUCKER, G.T. Pharmacokinetics of oral midazolam in children: 365P
JOHNSON, T.N., ROSTAMI-HODJEGAN, A., MATTHEWS, A., TUCKER, G.T. & BONHAM, J. Betaine kinetics in man: 386P
JOHNSON, T.N., TANNER, M.S., TAYLOR, C.J. & TUCKER, G.T. Enterocytic CYP3A4 in a paediatric population: developmental changes and the effect of coeliac disease and cystic fibrosis: 451
JOHNSTON, A. *see* WILSON, S.L. and KAVANAGH, S.L.
JONES, B.C. *see* HYLAND, R.
JONES, K., HOGGARD, P.G., KHOO, S., MAHER, B. & BACK, D.J. Co-prescribing of s & s in Australia: how often does it occur and who is doing it?: 99
JONES, L., ROSTAMI-HODJEGAN, A., PRATT, P., SEIVEWRIGHT, N., TUCKER, G.T. & LENNARD, M.S. Trends in the prescription of methadone to opiate users: a 34-month survey of the community health Sheffield (CHS) substance misuse service: 371P
JONES, S.J. *see* REILLY, J.G.
JONKMAN, J.H.G. *see* TAMMINGA, W.J.
JONVILLE-BÉRA, A.-P., AUTRET-LECA, E., BARBEILLON, F., PARIS-LLADO, J. & THE FRENCH REFERNCE CENTRE FOR SIDS, J. Outcomes of a randomized controlled trial of a clinical pharmacy intervention in 52 nursing homes: 271
JORKJEND, L. & SKOGLUND, L.A. A dose-response study of adrenaline combined with lignocaine 2%: effect on acute postoperative pain after oral soft tissue surgery: 335

KÄLLÉN, A. *see* ANDERSSON, N.
KANE, K. *see* SHIN, J.-G.
KARLSSON, M.O. *see* BRYNNE, L.
KARLSSON, M.O. *see* CULLBERG, M.
KAUFMAN, D.W. & KELLY FOR THE INTERNATIONAL CASE-CONTROL STUDY OF SEVERE CUTANEOUS ADVERSE REACTIONS, J.P. Acetysalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis: 177
KAVANAGH, P. *see* HENNESSEY, M.
KAVANAGH, S.L., BENJAMIN, N. & JOHNSTON, A. Detection of S-nitrosothiols in the stomach and plasma and the effect of nitrate ingestion in healthy volunteers: 377P
KELLEHER, D. *see* HENNESSEY, M.
KELLY FOR THE INTERNATIONAL CASE-CONTROL STUDY OF SEVERE CUTANEOUS ADVERSE REACTIONS, J.P. KAUFMAN, D.W.
KELLY, A. *see* WILLIAMS, D.
KENNEDY, M.A. *see* MARTIN, J.H.
KHALIQ, Y., GALLICANO, K., TISDALE, C., CARIGNAN, G., COOPER, C. & MCCARTHY, A. Comparison of the effects of nadolol and bisoprolol on the isoprenaline-evoked dilatation of the dorsal hand vein in man: 589
KHOO, S. *see* JONES, K.
KHOO, S.H. *see* BACK, D.J.
KIM, M.-K. *see* YOON, Y.-R.
KING, M.A. *see* ROBERTS, M.S.
KIRKPATRICK, C.J.M. *see* BEGG, E.J.
KLINKHARDT, U. *see* GRAFF, J.
KLUNGEL, O.H. *see* TEEUWISSE, A.K.
KNIBBE, C.A.J., ZUIDEVELD, K.P., DEJONGH, J., KUKS, P.F.M., AARTS, L.P.H.J. & DANHOF, M. Population pharmacokinetic and pharmacodynamic modelling of propofol 6% and propofol 1% for long term sedation in critically ill patient, 498P
KOKS, C.H.W., CROMMENTUYN, K.H.W., HOETELMANS, R.M.W., BURGER, D.M., KOOPMANS, P.P., MATHÔT, R.A.A., MULDER, J.W., MEENHORST, P.L. & BEIJNEN, J.H. Is eytochrome P450 2C9 genotype associated with NSAID gastric ulceration?: 629
KOOPMANS, P.P. *see* KOKS, C.H.W.
KORTH-BRADLEY, J.M. *see* SORAN, O.
KRAMERS, C. *see* VAN DEN BERG, E.J.
KUBOTA, T. & CHIBA, K. Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus: 475
KUKS, P.F.M. *see* KNIBBE, C.A.J.
KULLBERG, A. *see* PETERSEN, H.

LACARELLE, B. *see* PAGEAUX, G.P.
LAMBERT, D.G. *see* BIGONI, R.
LANCASTER, D.L., PATEL, N., LENNARD, L. & LILLEYMAN, J.S. Stopping rules for phase II studies: 531
LANGE, J.M.A. *see* VELDKAMP, A.I.
LANGLEY, R.W. *see* ABDELMAWLA, A.H.
LARSEN, H. *see* OLESEN, C.
LARSON, M.D. & TALKE, P.O. Drug treatment of obesity: from past failures to future successes?: 27
LARSON, S.M. *see* TANSWELL, P.
LARSSON, M. *see* CULLBERG, M.
LAURENT-PUIG, P. *see* MARCELLIN, P.
LE MOING, J.P. *see* PAGEAUX, G.P.
LEBRUN-VIGNES, B., CORBRION ARCHER, V., DIQUET, B., LEVRON, J.C., CHOSIDOW, O., PUECH, A.J. & WAROT, D. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects: 443
LEE, H.-R. *see* YOON, Y.-R.
LEE, H.S. *see* CHAN, E.
LEE, P.C.L., JAWAD, M.S.M., HULL, J.D., WEST, W.H.L., PORTER, K. & ECCLES, R. The effect of placebo treatment on cough associated with common cold: 373P
LENNARD, L. *see* LANCASTER, D.L.
LENNARD, M.S. *see* JONES, L. and ROSTAMI-HODJEGAN, A.
LEUFKENS, H.G.M. *see* MEIJER, W.E.E.
LEUFKENS, H.G.M. *see* SCHILLEVOORT, I.
LEUFKENS, H.G.M. *see* VAN STAAR, T.P.
LEVRON, J.C. *see* LEBRUN-VIGNES, B.
LEVRON, J.C. *see* PAGEAUX, G.P.
LILLEYMAN, J.S. *see* LANCASTER, D.L.

© 2001 Blackwell Science Ltd

LIM, Y.-C. *see* YOON, Y.-R.
LINDEMANS, A.D. *see* TEEUWISSE, A.K.
LINDEMANS, J. *see* VAN ROSSUM, L.K.
LING, S.S. *see* CAI, W.M.
LIPWORTH, B.J. *see* FOWLER, S.J.
LOCKTON, J.A. *see* HOOPER, W.D.
LOHMAN, J.J.H.M. *see* DERIJKS, L.J.J.
LOHMAN, J.J.H.M. *see* VAN DER KUY, P-H.M.
LUIPPOLD, G., SCHNEIDER, S., STEFANESCU, A., BENÖHR, P. & MÜHLBAUER, B. Dopamine D_2-like receptors and amino acid-induced glomerular hyperfiltration in humans: 415
LYNNE, T.A. *see* ROBERTS, M.S.

MACDONALD, T.M. *see* OLESEN, C.
MACFADYEN, R.J. *see* SHEHAB, A.M.A.
MAHER, B. *see* HENNESSEY, M.
MAHER, B. *see* JONES, K.
MAHMUD, A. & FEELY, J. Angiotensin II receptor antagonist reduces arterial stiffness in hypertensive patients; may be additive to ACE inhibition: 380P
MAHMUD, A. & FEELY, J. Pseudo-systolic hypertension in young men: elastic, not stiff arteries: 382P
MAHMUD, A. & FEELY, J. The effect of acute and chronic smoking on arterial stiffness in healthy young volunteers: 381P
MAINI, R. *see* BISWAS, N.R.
MAIOLINO, P. *see* PADRINI, R.
MAIXNER, W. *see* CREWS, K.R.
MAMET, J.P. *see* MARCELLIN, P.
MANN, D.L. *see* SORAN, O.
MANT, A. *see* MCMANUS, P.
MANUN'EBO, M. *see* HOOPER, W.D.
MARCELLIN, P., DE BONY, F., GARRET, C., ALTMAN, C., BOIGE, V., CASTELNAU, C., LAURENT-PUIG, P., TRINCHET, J.C., ROLAN, P., CHEN, C., MAMET, J.P. & BIDAULT, R. Influence of cirrhosis on lamotrigine pharmacokinetics: 410
MARTIN, J.H., BEGG, E.J., KENNEDY, M.A., ROBERTS, R. & BARCLAY, M.L. Recording previous adverse drug reactions—a gap in the system: 625
MÄRZ, W. *see* YATES, R.A.
MATHOT, R.A.A. *see* DE MAAT, M.M.R.
MATHÔT, R.A.A. *see* HUITEMA, A.D.R.
MATHÔT, R.A.A. *see* KOKS, C.H.W.
MATSUMOTO, S. & YAMAZOE, Y. Involvement of human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine: 133
MATTHEWS, A. *see* JOHNSON, T.N.
MAXWELL, S.R.J. *see* WARING, W.S.
MAZAGLIA, G.P. *see* ARCORACI, V.
MCCARTHY, A. *see* KHALIQ, Y.
MCCARTHY, S.T. *see* ROBERTS, M.S.
MCG. THOM., S.A. *see* WIMALASUNDERA, R.
MCGETTIGAN, P., GOLDEN, J., FRYER, J., CHAN, R. & FEELY, J. Prescribers prefer people: The sources of information used by doctors for prescribing suggest that the medium is more important than the message: 187
MCGOWAN, B. *see* RYAN, M.
MCLACHLAN, A.J. *see* GROSS, A.S.
MCMANUS, P., MANT, A., MITCHELL, P., BIRKETT, D. & DUDLEY, J. Risk factors in the development of adverse reactions to N-acetylcysteine in patients with paracetamol poisoning: 93
MCNAY, J.L. *see* BRYNNE, L.
MEENHORST, P.L. *see* DE MAAT, M.M.R.
MEENHORST, P.L. *see* KOKS, C.H.W.
MEENHORST, P.L. *see* VELDKAMP, A.I.
MEIJER, W.E.E., HEERDINK, E.R., PEPPLINKHUIZEN, L.P., VAN EIJK, J.T. & LEUFKENS, H.G.M. Prescribing patterns in patients using new antidepressants: 184
MELKERSSON, K.I., HULTING, A.-L. & RANE, A.J. Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses: 317
MEONI, P., HAUDIQUET, V., OTTO, M., POLLACK, M. & HACKETT, D. Predictive value of demographic and diagnostic factors for outcome in the treatment of generalized anxiety disorder: a pooled analysis of short term studies of venlafaxine ER: 363P
MERKUS, F.W.H.M. *see* VAN DER KUY, P-H.M.
MERRY, C. *see* BACK, D.J.
MERRY, C. *see* RYAN, M.
MERZ, M. *see* YATES, R.A.
MEULENDIJKS, C.F.M. *see* VAN DEN BERG, E.J.
MEYERS, T. *see* POWELL, J.
MICALLEF, J. *see* PAGEAUX, G.P.
MICHEL, M.C., BRESSEL, H.U., GOEPEL, M. & RÜBBEN, H. Public health impact of adverse bone effects of oral corticosteroids: 607
MILLERI, S. *see* ZIVIANI, L.
MINNS, I. *see* GROSS, A.S.
MINUTOLI L. *see* CALOGERO, G.F.
MITCHELL, P. *see* MCMANUS, P.
OHANTY, S. *see* ABERNETHY, D.R.
MORGAN, P. *see* OWEN, A.
MORICE, A.H. Research methods in human respiratory pharmacology: 287
MORICE, A.H. *see* ROSTAMI-HODJEGAN, A. and BUCK, H.
MORLEY, S.T. *see* POWELL, J.
MOTTRAM, D.R. *see* GREEN, C.F.
MOULY, S., AYMARD, G., TILLEMENT, J.P., CAULIN, C., BERGMANN, J.F. & URIEN, S. Simultaneous administration of a cocktail of markers to measure renal drug elimination pathways: absence of a pharmacokinetic interaction between fluconazole and sinistrin *p*-aminohippuric acid and pindolol: 555
MÜHLBAUER, B. *see* LUIPPOLD, G.
MULCAHY, F. *see* RYAN, M. and HENNESSEY, M.
MULCAHY, F.M. *see* CLARKE, S.M.
MULDER, J.W. *see* DE MAAT, M.M.R.
MULDEr, J.W. *see* KOKS, C.H.W.
MULDER, J.W. *see* VELDKAMP, A.I.
MULDER, W.M.C., DE KLERK, S., SETTELS, J.J., WESSELING, K.H. & VAN BOXTEL, C.J. Clockwise hysteresis of some concentration–cardiovascular effect relationships of terbutaline in man, 499P
MURTHY, B.P. *see* Crews, K.R.

NAUCK, M. *see* YATES, R.A.
NEEF, C. *see* VAN DER WILDT, J.J.
NEMAT, S., *see* POWELL, J.
NEWMAN, S.P. *see* DEWIT, O.
NICOLETTI, G. *see* ARCORACI, V.

O'KELLY, P. *see* WILLIAMS, D.
ODA, Y., HAMAOKA, N., HIROI, T., IMAOKA, S., HASE, I., TANAKA, K. FUNAE, Y., ISHIZAKI, T. & ASADA, A. Sudden unexpected death in infants udner 3 months of age and vaccination status – a case-control study: 281
OHRT, C. *see* ABERNETHY, D.R.
OLD, L.J. *see* TANSWELL, P.
OLESEN, C., DE VRIES, C.S., THRANE, N., MACDONALD, T.M., LARSEN, H., SORENSEN, H.T. & THE EUROMAP GROUP, H.T. Effect of diuretics on fetal growth: A drug effect or confounding by indication? Pooled Danish and Scottish cohort data: 153
OLSON, S.C. *see* BEGG, E.J.
OLSON, S.C. *see* BEGG, E.J.
OMARI, T. *see* WIERSMA, H.E.
OOSTERHUIS, B. *see* TAMMINGA, W.J.
OTAKE, Y. *see* WALLE, T.
OTTO, M. *see* MEONI, P.
OWEN, A., PIRMOHAMED, M., TETTEY, J.N., MORGAN, P., CHADWICK, D. & PARK, B.K. Carbamazepine is not a substrate for P-glycoprotein: 345
OXLADE, N. *see* CHARLETT, A.

PADRINI R. *see* SCORDO, M.G.
PADRINI, R., GUSELLA, M., ALBUNNI, M., MAIOLINO, P. & FERRARI, M. Are QT correction

formulas reliable in measuring drug-induced QT interval prolongation?: 370P
PAGEAUX, G.P., MICALLEF, J., BARUGOLA NATAF, M., LEVRON, J.C., LACARELLE, B., LE MOING, J.P., BOUHOURS, P. & BLIN, O. Pharmacokinetics of sabeluzole and dextromethorphan oxidation capacity in patients with severe hepatic dysfunction and healthy volunteers: 167
PALMER, J.L. *see* CREWS, K.R.
PARIANTE, C.M. Fundamentals of Psychoneuroimmunology: 196
PARIS-LLADO, J. *see* JONVILLE-BÉRA, A.-P.
PARK, B.K. *see* OWEN, A.
PARK, J.-Y. *see* YOON, Y.-R.
PASSANNANTE, A.N. *see* CREWS, K.R.
PATEL, N. *see* LANCASTER, D.L.
PENGO, V. *see* SCORDO, M.G.
PEPPLINKHUIZEN, L.P. *see* MEIJER, W.E.E.
PEREIRA, A. *see* DALEY-YATES, P.T.
PETERSEN, H., KULLBERG, A., EDSBÄCKER, S. & GREIFF, L. Nasal retention of budesonide and fluticasone in man: Formation of airway mucosal budesonide-esters *in vivo*: 159
PETERSON, D.W. *see* CHARLETT, A.
PEZZULLO, J.C. *see* ABERNETHY, D.R.
PHUÖNG, H.L. *see* BINH, T.Q.
PHUONG, V.D.B. *see* BINH, T.Q.
PIETERS, M.S.M. *see* DE VISSER, S.J.
PIRMOHAMED, M. *see* GREEN, C.F.
PIRMOHAMED, M. *see* OWEN, A.
POLLACK, M. *see* MEONI, P.
PORSIUS, A.J. *see* TEEUWISSE, A.K.
PORSIUS, A.J. *see* VAN DE VIJVER, D.A.M.C.
PORTER, K. *see* LEE, P.C.L.
POSVAR, E.L. *see* BEGG, E.J.
POSVAR, E.L. *see* BEGG, E.J.
POULTER, N. *see* WILSON, S.L.
POWELL, J., MEYERS, T., MORLEY, S.T., NEMAT, S., WINSPER, S.J. & GLOVER, D.R. Pharmacokinetics of CAT-192, a fully human monoclonal IgG4 antibody, following single intravenous administration to humans: 389P
POWELL, S.M. *see* BINH, T.Q.
PRATT, P. *see* JONES, L.
PRICE, A.C. *see* DALEY-YATES, P.T.
PUECH, A.J. *see* LEBRUN-VIGNES, B.
PURDIE, D.M. *see* ROBERTS, M.S.

RADEMAKER, M.V. *see* EDELBROEK, P.M.
RADKE, J. *see* SCHMUCK, S. and BRODDE, O.-E.
RANE, A.J. *see* MELKERSSON, K.I.
REECE, P.A. *see* BEGG, E.J.
REECE, P.A. *see* BEGG, E.J.
REGAN, L. *see* WIMALASUNDERA, R.
REILLY, J.G., AYIS, A.S., FERRIER, I.N., JONES, S.J. & THOMAS, S.H.L. Sudden death and thioridazine: 363P
RETTIg, W.J. *see* TANSWELL, P.
REYNOLDS, H.E. *see* CLARKE, S.M.
RITCHIE S. *see* DEWIT, O.
RITTER, J.M. *see* WALKER, H.A.
ROBB, T. *see* SHENFIELD, G.M.
ROBERTS, M.S., STOKES, J.A., KING, M.A., BONNER, C.J., LYNNE, T.A., PURDIE, D.M., GLASZIOU, P.P., WILSON, D.A.J., MCCARTHY, S.T., BROOKS, G.E., DE LOOZE, F.J. & DEL MAR, C.B. Identification in the cytochrome P450 enzymes involved in the *N*-demethylation of sildenafil: 257
ROBERTS, R. *see* MARTIN, J.H.
ROBSON, J. *see* WILSON, S.L.
ROBSON, R.A. *see* BEGG, E.J.
ROBSOn, R.A. *see* BEGG, E.J.
RODENHUIS, S. *see* HUITEMA, A.D.R.
ROE, E.G.H. *see* HYLAND, R.
ROLAN, P. *see* MARCELLIN, P.
ROOS, R.A.C. *see* SCHILLEVOORT, I.
ROOS, R.A.C. *see* VAN DE VIJVER, D.A.M.C.
ROSTAMI-HODJEGAN, A. & TUCKER, G.T. Journal impact factors: a 'bioequivalence' issue?: 111
ROSTAMI-HODJEGAN, A. *see* JOHNSON, T.N.
ROSTAMI-HODJEGAN, A. *see* JONES, L.
ROSTAMI-HODJEGAN, A., ABDUL-MANAP R., WRIGHT, C.E., LENNARD, M.S., MORICE, A.H. & TUCKER, G.T. Dextromethorphan (DEX) is a more potent antitussive that its metabolite, dextrorphan (DOR): 372P
ROWBOTHAM, D.J. *see* BIGONI, R.
ROWE, P.H. *see* GREEN, C.F.
RÜBBEN, H. *see* MICHEL, M.C.
RUIJTEr, R. *see* VERSCHRAAGEN, M.
RUSSEL, F.G.M. *see* VAN DER KUY, P-H.M.
RYAN, C. *see* RYAN, M.
RYAN, K.K. *see* FLEISHAKER, J.C.
RYAN, M., MERRY, C., RYAN, C., HEEREY, A., MCGOWAN, B., MULCAHY, F. & BARRY, M. Determining the cost of HIV inpatient care in Ireland in order to evaluate the pharmacoeconomic impact of HAART on hospitalisation costs: 385P

SARIS, W.H.M. *see* VAN BAAK, M.A.
SCHAEFER, H.G. *see* BRYNNE, L.
SCHELLENS, J.H.M. *see* HUITEMA, A.D.R.
SCHILLEVOORT, I., VAN PUIJENBROEK, E.P., DE BOER, A., ROOS, R.A.C., JANSEN, P.A.F. & LEUFKENS, H.G.M. Extrapyramidal syndromes associated with SSRI use, 496P
SCHMIDT, L.E. & DALHOFF, K. Attitudes of hospital pharmacists to adverse drug reaction reporting: 87
SCHMUCK, S., TELLKAMP, R., BÜSCHER, R., EILMES, K.J., DHEIN, S., RADKE, J. & BRODDE, O.-E. Functional role of the Thr164I1E polymorphism of the β_2-adrenoreceptor: *in vivo* studies in healthy volunteers: 367P
SCHNEIDER, S. *see* LUIPPOLD, G.
SCHNEIDER, V.M. *see* SORAN, O.
SCHNURRER, J.U., STICHTENOTH, D.O., TROOST, R. & FRÖLICH, J.C. Drug expenditure in hospitals: what do German ward physicians know?: 342
SCHOEMAKER, R.C. *see* DE VISSER, S.J.
SCHREIJ, G. *see* VELDKAMP, A.I.
SCHULLER-PETROVIC, S. *see* BRUNNER, F.
SCHUSTER, B.G. *see* ABERNETHY, D.R.
SCORDO, M.G., SPINA, E., BELLOCCO, G. & ALTAVILLA G. Influence of *CYP2C9* polymorphism in lung cancer susceptibility: 375P
SCORDO, M.G., SPINA, E., DAHL, M.L., PENGO, V. & PADRINI R. Effect of *CYP2C9* polymorphism on warfarin maintenance dose and plasma S:R ratio: 375P
SCOTT, A.M. *see* TANSWELL, P.
SEDMAN, A.J. *see* BEGG, E.J.
SEDMAN, A.J. *see* BEGG, E.J.
SEIBERLING, M. *see* YATES, R.A.
SEIVEWRIGHT, N. *see* JONES, L.
SERVELLO, M.M. *see* CALOGERO, G.F.
SETTELS, J.J. *see* MULDER, W.M.C.
SEYMOUR, H.E., WORSLEY, A., SMITH, J.M. & THOMAS, S.H.L. *Genes for common diseases edited by Prof. M.J. Caulfield*, 201
SHABESTARI, O.L. *see* AKHONDZADEH, S.
SHEHAB, A.M.A., BUTLER, R., MACFADYEN, R.J. & STRUTHERS, A.D. A placebo-controlled study examining the effect of allopurinol on heart rate variability and dysrhythmia counts in chronic heart failure: 329
SHENFIELD, G.M., ROBB, T. & DUGUID, M. Drug therapy in the elderly: what doctors believe and patients actually do: 621
SHIN, J.-G. *see* YOON, Y.-R.
SHIN, J.-G., KANE, K. & FLOCKHART, D.A. Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure: 45

SHON, J.-H. *see* YOON, Y.-R.
SIDDIQUEI, M.M. *see* BISWAS, N.R.
SISSON, J.R. *see* DALEY-YATES, P.T.
SJÖQVIST, F. Non-responders in clinical pharmacology – a commentary to a book review by D.N. Bateman: 194
SKOGLUND, L.A. *see* JORKJEND, L.
SMITH, D.A. *see* HYLAND, R.
SMITH, J.M. *see* SEYMOUR, H.E.
SONG, E., CHEN, J. & SU, F. Chemotherapy sensitivity of human colon carcinoma relative to glutathione-S-transferase II expression: 366P
SORAN, O., FELDMAN, A.M., SCHNEIDER, V.M., HANNA, R., MANN, D.L. & KORTH-BRADLEY, J.M. The pharmacokinetics of etanercept in patients with heart failure: 193
SORENSEN, H.T. *see* OLESEN, C.
SPIGSET, O. *see* HÄGG, S.
SPINA, E. *see* SCORDO, M.G.
SQUASSANTE, L. *see* ZIVIANI, L.
STALLARD, N. *see* TODD, S.
STALLARD, N. *see* WHITEHEAD, J.
STALLARD, N., WHITEHEAD, J., TODD, S. & WHITEHEAD, A. *Research Methods in Human Cardiovascular Pharmacology edited by Dr S. Maxwell and Prof. D. Webb*, 523
STEFANESCU, A. *see* LUIPPOLD, G.
STICHTENOTH, D.O. *see* SCHNURRER, J.U.
STOKES, J.A. *see* ROBERTS, M.S.
STRUIJKER-BOUDIER, H.A.J. *see* DE HOON, J.N.J.M.
STRUPISH, J.W. *see* BIGONI, R.
STRUTHERS, A.D. *see* SHEHAB, A.M.A.
SU, F. *see* SONG, E.
SWEDBERG, K. *see* BRYNNE, L.
SZABADI, E. *see* ABDELMAWLA, A.H.

TALKE, P.O. *see* LARSON, M.D.
TAMMINGA, W.J., WEER, J., OOSTERHUIS, B., WIELING, J., TOUW, D.J., DE ZEEUW, R.A., DE LEIJ, L.F.M.H. & JONKMAN, J.H.G. Mephenytoin as a probe for CYP2C19 phenotyping: effect of sample storage, intra-individual reproducibility and occurrence of adverse events: 471
TANAKA, K. *see* ODA, Y.
TANNER, M.S. *see* JOHNSON, T.N.
TANSWELL, P., GARIN-CHESA, P., RETTIG, W.J., WELT, S., DIVGI, C.R., CASPER, E.S., FINN, R.D., LARSON, S.M., OLD, L.J. & SCOTT, A.M. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients: 180
TAYLOR, C.J. *see* JOHNSON, T.N.
TEEUWISSE, A.K., LINDEMANS, A.D., VERSCHUREN, W.M.M., KLUNGEL, O.H., PORSIUS, A.J. & DE BOER, A. Under-treatment of hypercholesterolaemia in a population-based study in the Netherlands, 496P
TELLKAMP, R. *see* SCHMUCK, S. and BRODDE, O.-E.
TETT, S.E. *see* GROSS, A.S.
TETTEY, J.N. *see* OWEN, A.
THE EUROMAP GROUP, H.T. *see* OLESEN, C.
THE FRENCH REFERNCE CENTRE FOR SIDS, J. *see* JONVILLE-BÉRA, A.-P.
THIEN, H.V. *see* BINH, T.Q.
THOMAS, S.H.L. *see* REILLY, J.G., or EL ERAKY, H.
THOMAS, S.H.L. *see* SEYMOUR, H.E.
THORSSON, L. *see* ANDERSSON, N.
THRANE, N. *see* OLESEN, C.
THU, L.T.A. *see* BINH, T.Q.
TIBBEN, M.M. *see* HUITEMA, A.D.R.
TILLEMENT, J.P. *see* MOULY, S.
TISDALE, C. *see* KHALIQ, Y.
TJIA, J. *see* CLARKE, S.M.
TJIA, J. *see* HENNESSEY, M.
TODD, S. *see* STALLARD, N.
TODD, S. *see* WHITEHEAD, J.
TODD, S., WHITEHEAD, A., STALLARD, N. & WHITEHEAD, J. Interim analyses and sequential designs in phase III studies: 394
TOUBRO, S. *see* VAN BAAK, M.A.
TOUW, D.J. *see* TAMMINGA, W.J.
TOUZE, E. *see* FOURRIER, A.
TRINCHET, J.C. *see* MARCELLIN, P.
TROOST, J. *see* DE HOON, J.N.J.M.
TROOST, R. *see* SCHNURRER, J.U.
TUCKER, G.T. *see* JOHNSON, T.N.
TUCKER, G.T. *see* JOHNSON, T.N.
TUCKER, G.T. *see* JOHNSON, T.N.
TUCKER, G.T. *see* JONES, L. and ROSTAMI-HODJEGAN, A.
TUCKER, G.T. *see* ROSTAMI-HODJEGAN, A.

URIEN, S. *see* MOULY, S.

VAN BAAK, M.A., HUL, G., TOUBRO, S., ASTRUP, A., GOTTESDIENER, K. M., DESMET, M., SARIS, W.H.M. Acute thermogenic effect of L-796568, a novel β_3-adrenoceptor agonist, in obese men, 500P
VAN BORTEL, L.M.A.B. *see* DE HOON, J.N.J.M.
VAN BOXTEL, C.J. *see* MULDER, W.M.C.
VAN BOXTEL, C.J. *see* WIERSMA, H.E.
VAN DE VIJVEr, D.A.M.C., ROOS, R.A.C., JANSEN, P.A.F., PORSIUS, A.J. & DE BOER, A. Use of antidepressants in Parkinson's disease; association with disease and its course, 495P
VAN DEN BERG, E.J., VAN DER WILT, G.J., MEULENDIJKS, C.F.M., DROOGLEEVER-FORTUYN, H., VERKEs, R.J. & KRAMERS, C. Autointoxication patients: who need to be admitted and how long should th observation period be to make this decision?, 494P
VAN DER GEEST, S. *see* VELDKAMP, A.I.
VAN DER KUY, P-H.M., MERKUS, F.W.H.M., RUSSEL, F.G.M., LOHMAN, J.J.H.M. & HOOYMANS, P.M. Pharmacokinetics of intranasal and oral hydroxocobalamin in healthy subjects, 505P
VAN DER MEULEN, J. *see* CLEOPHAS, T.J.
VAN DER POST, J. *see* DE VISSER, S.J.
VAN DER VIJGH, W.J.F. *see* VERSCHRAAGEN, M.
VAN DER WILDT, J.J. & NEEF, C. The pineal gland as an infusion system, a pharmacokinetic approach to melatonin, 503P
VAN DER WILT, G.J. *see* VAN DEN BERG, E.J.
VAN EIJK, J.T. *see* MEIJER, W.E.E.
VAN GERVEN, J.M.,A. *see* DE VISSER, S.J.
VAN GERVEN, J.M.A. *see* DE VISSER, S.J.
VAN GORP, E.C.M. *see* de MAAT, M.M.R.
VAN HEESWIJK, R.P.G. *see* VELDKAMP, A.I.
VAN KRAAIJ, D.J.W., VOLLAARD, E.J., DE METZ, M. & WITTERLAND, A. A comparison of the effects of nabumetone *vs* meloxicam on serum thromboxane B_2 and platelet function, 499P
VAN MARUM, R. *see* CLEOPHAS, T.J.
VAN MARUM, R. *see* CLEOPHAS, T.J.
VAN OUWERKERK, B.M. *see* CLEOPHAS, T.J.
VAN PUIJENBROEK, E.P. *see* SCHILLEVOORT, I.
VAN ROSSUm, L.K., CRANSBERG, K., K., DERKX, F., LINDEMANS, J., DE RIJKE, Y.B., ZIETSE, R. & VULTO, A.G. The result of determination of the GFR in children by the inulin single-injection method is computer software dependent, 502P
VAN STAAR, T.P., ABENHAIM, L., COOPER, C., ZHANG, B. & LEUFKENS, H.G.M. Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers: 599
VELDKAMP, A.I., VAN HEESWIJK, R.P.G., MULDER, J.W., MEENHORST, P.L., SCHREIJ, G., VAN DER GEEST, S., BEIJNEN, J.H., LANGE, J.M.A. & HOETELMANS,

R.M.W. The steady-state pharmacokinetics of saquinavir (SQV-SGC, Fortovase™) 1000 mg twice daily in combination with ritonavir (RIT) 100 mg twice daily in HIV-infected individuals after a normal and a high fat breakfast, 497P
VERDIER-TAILLEFER, M.-H. *see* FOURRIER, A.
VERKES, R.J. *see* VAN DEN BERG, E.J.
VERMEIJ, T.A.C. *see* EDELBROEK, P.M.
VERSCHRAAGEN, M., BOVEN, E., RUIJTER, R., WESTERMAN, M., HAUSHEER, F.H. & VAN DER VIJGH, W.J.F. Pharmacokinetics of (hydrated)cisplatin and (di)mesna during a phase 1 study of BNP7787 and cisplatin in cancer patients, 504P
VERSCHUREN, W.M.M. *see* TEEUWISSE, A.K.
VOLLAARD, E.J. *see* VAN KRAAIJ, D.J.W.
VOUSDEN M. *see* DEWIT, O.
VULTO, A.G. *see* VAN ROSSUM, L.K.

WALKER, H.A., JACKSON, G., RITTER, J.M. & CHOWIENCZYK, P.J. The pharmacokinetics of methadone in -positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz: 225
WALLE, T., OTAKE, Y., BRUBAKER, J.A., WALLE, U.K. & HALUSHKA, P.V. Disposition and metabolism of the flavonoid chrysin in normal volunteers: 143
WALLE, U.K. *see* WALLE, T.
WARING, W.S., ADWANI, S.H., WEBB, D.J. & MAXWELL, S.R.J. Increased FiO_2 causes increased baroreflex sensitivity in healthy volunteers: 368P
WARING, W.S., GOOD, A.M. & BATEMAN, D.N. Lithium toxicity: National Poisons Information Service (Edinburgh Centre) enquiries: 378P
WAROT, D. *see* LEBRUN-VIGNES, B.
WEER, J. *see* TAMMINGA, W.J.
WEBB, D.J. *see* WARING, W.S.
WELLER, C. *see* CHARLETT, A.
WELT, S. *see* TANSWELL, P.
WESCHE, D.L. *see* ABERNETHY, D.R.
WESSELING, K.H. *see* MULDER, W.M.C.
WEST, W.H.L. *see* LEE, P.C.L.
WESTERMAN, M. *see* VERSCHRAAGEN, M.
WESTRUP, D. *see* GRAFF, J.
WHEATLEY, A.P. *see* FENECH, A.G.
WHITEHEAD, A. *see* STALLARD, N.
WHITEHEAD, A. *see* TODD, S.
WHITEHEAD, A. *see* WHITEHEAD, J.
WHITEHEAD, J. *see* STALLARD, N.
WHITEHEAD, J., TODD, S., WHITEHEAD, A. & STALLARD, N. Interim analyses in clinical trials: 393
WIELING, J. *see* TAMMINGA, W.J.
WIERSMA, H.E., BENNINGA, M., BUTTER, J.J., OMARI, T. & VAN BOXTEL, C.J. Pharmacokinetics of baclofen in paediatric patients with gastro-oesophageal reflux disease, 501P
WILLIAMS, D. & FEELY, J. Co-prescribing with nitrate therapy shows neglect in secondary prevention: 379P
WILLIAMS, D. & FEELY, J. Initial uptake and co-prescribing patterns of sildenafil: 384P
WILLIAMS, D., O'KELLY, P., KELLY, A. & FEELY, J. Adherence to anti-hypertensive medications, including combinations, in primary care: 379P
WILLIAMS, G. *see* COLLINS, P.
WILSON, D.A.J. *see* ROBERTS, M.S.
WILSON, S.L., JOHNSTON, A., COLLIER, D.J., FEDER, G., ROBSON, J., POULTER, N. & CAULFIELD, M. The impact of high density lipoprotein and left ventricular hypertrophy on risk assessments made using the Framingham coronary heart disease equation: 369P
WILTSE, C.G. *see* BRYNNE, L.
WIMALASUNDERA, R., REGAN, L., McG. THOM., S.A. & HUGHES, A.D. BQ-123 is a selective endothelin-1 antagonist but has little effect on basal forearm blood flow in man: 368P
WINSPER, S.J. *see* POWELL, J.
WITTERLAND, A. *see* VAN KRAAIJ, D.J.W.
WONG, J. *see* YATES, R.A.
WORSLEY, A. *see* SEYMOUR, H.E.
WRAY, H. *see* DEWIT, O.
WRIGHT, C.E. *see* ROSTAMI-HODJEGAN, A.

YAMAZOE, Y. *see* MATSUMOTO, S.
YATES, R.A., WONG, J., SEIBERLING, M., MERZ, M., MÄRZ, W. & NAUCK, M. The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers: 429
YEO K.R. *see* YEO, W.W.
YEO, K.R. & YEO, W.W. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes: 461
YEO, W.W. & YEO K.R. Predicted impact of the National Service Framework for coronary heart disease on statin prescribing: 383P
YEO, W.W. *see* YEO, K.R.
YOON, Y.-R., SHON, J.-H., KIM, M.-K., LIM, Y.-C., LEE, H.-R., PARK, J.-Y., CHA, I.-J. & SHIN, J.-G. Patterns of prescription and drug use in ophthalmology in a tertiary hospital in Delhi: 277

ZHANG, B. *see* VAn Staar, T.P.
Zhang, Y.D. *see* Cai, W.M.
Zietse, R. *see* van Rossum, L.K.
Ziviani, L., Da Ros, L., Squassante, L., Milleri, S., Cugola, M. & Iavarone, L.E. The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects: 147
Zuideveld, K.P. *see* Knibbe, C.A.J.
Zwinderman, A.H. *see* Cleophas, T.J.

© 2001 Blackwell Science Ltd

SUBJECT INDEX

This index was compiled from the keywords
(P = Proceedings, S = Supplement)

α_1-acid glycoprotein, 99
Abciximab, 575
Absolute bioavailability, 400
ACE inhibition, 380P
ACE inhibitors, 493P
Acetaminophen, 209
Acetaminophen, 87
Acetylcholine, 225
Acetylsalicylic acid, 174
Activated partial thromboplastin time, 71, 429
Adrenaline, 335
Adverse drug events, 377P
Adverse drug reaction, 81
Adverse drug reactions, 621
Adverse effects, 209
Aetiology, 271
Aged, 257, 613
Airway, 159
Albuterol, 225
Aldosteronism, 5
Allopurinol, 329
Amino acids, 415
Anaesthetics, 27
Anastrozole, 429
Angiotensin II receptor antagonist, 380P
Angiotensinogen, 5
Antibiotic prescriptions, 371P
Anticoagulant activity, 429
Anticoagulation, 71
Antidepressants, 181, 495P
Antiepileptic drugs, 494P
Anti-hypertensive medication, 379P
Antipsychotic agents, 317
Antipsychotic, 119
Anti-TNF agents, 201
Antitussive, 372P
APTT, 71
Aqueous nasal spray, 374P
Arterial stiffness, 380P, 381P
Artesunate, 539
Astemizole, 133
Asthma, 87, 390P
Atopy, 87
Autointoxication, 494P
Azothioprine, 503P

β-adrenoceptors, 581
β_1-adrenoceptor, 367P
β_2-adrenoceptor, 359, 367P
β_3-adrenoceptor agonist, 500P
β-adrenoceptor antagonists, 493P
Baclofen, 364P, 501P
Baroreflex sensitivity, 368P
Beclomethasone diproprionate, 400
Beclomethasone-17-monoproprionate, 400
Benign prostatic hyperplasia, 607
Betaine, 386P
Bioavailability, 103, 143, 539
Biomarker, 119
Bisoprolol, 581
Body mass index, 317
BQ-123, 368P
Budesonide, 325, 373P

Calcium channel blockers, 493P
Cancer patients, 177
Cancer, 504P
Carbamazepine, 345, 565
Case-control study, 271
CAT-192, 389P
CD4, 555
Chemotherapy sensitivity, 366P
Childhood lymphoblastic leukaemia, 531
Children and adults, 565
Children, 365P, 451
Chronic liver disease, 164
Chrysin metabolism, 143
Chrysin, 143
Cirrhosis, 410
Cisplatin, 504P
Clinical pharmacology, 111
Clinical pharmacy services, 257
Clinical trial design, 393, 523
Clonidine, 364P
Coeliac disease, 451
Cognition, 119
Committee on Safety of Medicines, 81
Common cold, 373P, 374P
Complex traits, 195
Confounding by indication, 153
Coprescribing, 93
Coronary heart disease, 369P, 383P
Corticosteroids, 443
Cortisol ratio, 350
Cortisol, 325
Cost containment, 342
Cost effectiveness, 257
Cotinine, 53
Cough, 373P
Creatinine clearance, 545
Cyclosporin, 387P
CYP2C19, 169, 471
CYP2C9 polymorphism, 375P
CYP2C9, 277, 625
CYP2D6, 45, 133, 169
CYP3A, 350
CYP3A4, 133, 451, 461
Cystic fibrosis, 451
Cytochrome P450 3A4, 589
Cytochrome P450 enzymes, 239
Cytochrome P450, 133, 169, 209
Cytochrome P4502B6, 281
Cytoprotection, 209

Daily therapeutic doses, 342
Demyelinating disorders, 489
Development of drugs, 267
Dexmedetomidine, 27
Dextromethorphan oxidation, 164
Dextromethorphan, 107, 372P
Dextrophan, 372P
Diabetes mellitus, 493P
Diabetes, 195
Diarrhoea, 555
Dihydroartemisinin, 539
Dihydropyridine calcium channel blockers, 506P
Diltiazem, 461
Dimesna, 504P
Diuretics, 153
Dopamine D_2-like receptors, 415
Dorsal hand vein, 581
Drug expenditure, 342
Drug interaction, 87, 249, 607, 629
Drug interactions, 239, 350, 389P
Drug metabolism, 209
Drug prescriptions, 613
Drug therapy, 613
Drug utilization, 93, 257
Drug-drug interactions, 443, 497P
Dry powder inhalers, 373P
Duodenum, 451
Dysrhythmia, 329

Early stopping, 393, 523
Education, 257
Efavirenz, 213
Emergency departments, 377P
Enalapril, 482
Enantiomer, 45
Endomorphin 1, 355
Endothelin-1 antagonist, 368P
Endothelium, 225
Epilepsy, 249, 345
Erythromycin breath test, 589
Etanercept, 191
Ethinyloestradiol, 169
Extrapyramidal syndromes, 496P

Factor VII, 429
Falciparum malaria, 539
Fetal growth, 153
Fibroblast activation protein, 177
Flavonoids, 143
Fluconazole, 545, 629
Fluticason propionate nasal drops, 103
Fluticasone propionate aqueous nasal spray, 103
Fetus, 451
Food, 497P, 531
Forearm blood flow, 368P
Fractures, 599

© 2001 Blackwell Science Ltd

Framingham equation, 369P

Gamma scintigraphy, 289
Gastric ulcer, 625
Gender, 169, 366P, 376P
Gene identification, 195
Generalised anxiety disorder, 363P
Genes, 5
Genotype, 277, 475
Glomerular filtration rate, 502P
Glomerular hyperfiltration, 415
Glucagon-like peptide-1, 13
Glucocorticosteroid, 159
Glutathione-S-transferase π expression, 366P
Gly389Arg polymorphism, 367P
Group sequential designs, 393, 523

Halofantrine, 231
Haloperidol, 45
Healthy volunteers, 143
Heart failure, 191, 329, 482, 506P
Heart rate variability, 329
Heart rate, 35
Helicobacter pylori, 388P
Hepatitis B vaccine, 489
High density lipoprotein, 369P
High dose chemotherapy, 61
HIV infection, 555
HIV, 99, 213, 385P
HIV-1 infection, 497P, 629
HMGCoA reductase inhibitors, 147
Hospital pharmacists, 81
Hospital, 342
5-$HT_{1B/1D}$- receptor agonist, 501P
Human colon carcinoma, 366P
Human liver microsomes, 133
Human monoclonal IgG4 antibody, 389P
Human native nociceptin receptors, 355
Human vas deferens, 355
Human, 13, 159
Hydroxocobalamin, 505P
3′-Hydroxycotinine, 53
Hypercholesterolaemia, 496P
Hyperprolactinaemia, 317
Hypertension, 5, 380P, 423, 493P
Hysteresis, 499P

Idiopathic parkinsonism, 388P
Indinavir, 385P
Inflammatory bowel disease, 503P
Inhalation, 289
Inhaled corticosteroids, 325
Inhaled, 400
Inhibition, 45
Inhibitory quotient, 301
Inogatran, 71
Insulin action, 195
Insulin secretion, 195
Insulin-like growth factor I, 317
Interaction, 45, 147, 461
Intestine, 451
Intracellular accumulation, 99
Intranasal, 400
Intravenous, 400

Inulin method, 502P
Ischaemic stress, 329
Itraconazole, 443

Japanese, 475
Journal impact factor, 111

Korean, 277

L-796568, 500P
Lacidipine, 147
Lamotrigine, 410
Left ventricular hypertrophy, 369P
Leptin, 13
Light reflex, 27
Lignocaine, 335
Lithium toxicity, 378P
Liver, 281
Long term care, 257
Lung cancer, 375P
Lung deposition, 289, 400

mAbF19, 177
Mean heart rate, 329
Medical audit, 267
Medical records, 497P, 621
Mefloquine, 589
Melanocortin-4 receptor, 13
Melatonin, 503P
Meloxicam, 499P
Mephenytoin, 471
6-mercaptopurine, 503P
Metabolism, 53 281
Metabolites, 45
Methadone, 213, 350, 371P
Midazolam, 365P
Migraine, 437, 501P
Milk, 478
Monoamine oxidase, 437
Monoclonal antibody, 177
Monogenic, 5
Morphine, 309
Morphine-3-glucuronide, 309
Morphine-6-glucuronide, 309
Mortality, 329
Moxonidine, 35
Muscarinic M_2 receptors, 390P
Muscarinic M_3 receptors, 390P
Muscarinic receptors, 390P
Mutations, 5

Nabumetone, 499P
N-acetylcysteine, 87
Nadolol, 581
Naloxone, 355
Nasal, 159
National Poisons Information Service (Edinburgh Centre), 378P
National Service Framework, 383P
Neuripeptide Y, 13
Nicotine, 53
Nitrate therapy, 379P
Nitric oxide, 329
Nociceptin, 355
NONMEM, 565

Noradrenaline, 35, 581
NSAIDs, 625
Nursing homes, 257

Obesity, 13
Obesity, 500P
Once daily, 325
Ondansetron, 309
Opiate users, 371P
Opiate withdrawal, 364P
Oral cavity infections, 371P
Oral contraceptives, 169
Oral corticosteroids, 599
Oral ganciclovir, 555
Oral surgery, 335
Oral, 400
Orexins, 13
Orlistat, 13
Oxidant stress, 329
Oxygen delivery, 368P

Paediatric patients, 501P
Paediatrics, 451
Paracetamol, 87, 209
Parkinson's disease, 495P
Patient care team, 257
Patient compliance, 613
Patient nonadherence, 613
Patient outcome, 257
Patient safety, 267
P-glycoprotein, 345, 389P
Pharmacodynamic modelling, 35, 498P
Pharmacodynamics, 53, 309, 423, 429, 539
Pharmacoeconomic impact, 385P
Pharmacoenhancement, 301
Pharmacoepidemiology, 181
Pharmacogenetics, 107, 565
Pharmacokinetic interaction, 589
Pharmacokinetic modelling, 498P
Pharmacokinetics, 53, 61, 164, 191, 249, 289, 309359, 365P, 366P, 373P, 385P, 386P, 389P, 400, 410, 423, 429, 437, 443, 478, 497P, 501P, 503P, 504P, 505P, 531, 539
Pharmacotherapy, 219
Pharmacy records, 497P
[Phe^1 ψ(CH_2-NH)Gly^2]NC(1-13)NH_2, 355
Phenobarbitone, 249
Phenotype, 169
Phenotyping, 471
Pindolol, 545
Pineal gland, 503P
Placebo treatment, 373P
Platelet derived growth factor, 575
Platelet function, 499P
Poisoning, 87
Population pharmacodynamic modelling, 71
Population pharmacokinetics, 177, 555, 565
Postoperative pain, 335
Pregnancy, 153
Prescibers, 184
Prescribing information, 184
Prescribing patterns, 181, 267
Prescribing, 184

© 2001 Blackwell Science Ltd

Prescription, 371P
Primary care, 379P
Primary varicosity, 219
Prolactin, 119
Propofol, 281, 498P
Protease inhibitors, 99, 301
Prothrombin time, 429
P-selectin, 575
Pseudo-systolic hypertension, 382P
Psychomotor performance, 388P
Public health, 599
Pulmonary function, 482
Pulse wave analysis, 507
Pupil size, 27

QT correction formulae, 370P
QT dispersion, 376P
QT interval, 370P
QTc, 231
Quality use of medicines, 184
Questionnaire survey, 342
Quinapril, 478
Quinaprilat, 478
Quinidine, 366P, 376P

Rate, 423
Rational drug therapy, 342
Rational prescribing, 184
Reduced haloperidol, 45
Reflex dilation, 27
Remacemide, 249
Renal drug elimination, 545
Renal transplant patients, 387P
Renin, 5
Reproducibility, 225
Research assessment, 111
Rheumatoid arthritis, 201
Rhinitis, 159
Rilmenidine, 423
Risk assessment, 369P
Risk factor, 87
Ritonavir, 497P, 589, 629

Sabeluzole, 164
Salbutamol, 359
Saquinavir, 497P, 629
Scintigraphy, 374P
Secondary prevention, 379P
Selective serotonin reuptake inhibitors, 93, 181, 496P
Self poisoning, 494P
Serotonin agonist, 437
Sex differences, 317
Sibutramine, 13
Side effects, 87
Sildenafil, 239, 384P
Simvastatin, 147461
Singapore epileptic patients, 565
Smoking, 53, 381P
Smooth muscle contractility, 219
S-nitrosothiols, 377P
St John's Wort, 389P
Statin prescribing, 383P
Stereoselective clearance, 231
Stevens–Johnson syndrome, 174
Strain gauge plethysmography, 225
Sudden death, 363P
Sudden unexpected death, 271
Survey, 81
Systemic delivery, 289
Systolic blood pressure, 35

Tamoxifen, 209
Tamsulosin, 607
Terbinafine, 107
Terbutaline, 499P
Terfenadine, 133
Therapeutic drug monitoring, 301, 494P
Thermogenic agents, 13
6-Thioguanine nucleotides, 531
6-Thioguanine, 531
Thioridazine, 363P
ThioTEPA, 61
Thr164I1E polymorphism, 367P
Thrombin inhibition, 71
Thrombin time, 429
Thromboxane B_2, 499P
Tobacco, 53
Tolerability, 607
Toxic epidermal necrolysis, 174
*TPMT*3C*, 475
Treatment, 159
Tricyclic antidepressants, 93
Tubular secretion, 545
Tubular reabsortion, 545
Tumour necrosis factor, 201

U937 cells, 99
UK-103 320, 239
Uncoupling proteins, 13
Uric acid, 329

Vaccination status, 271
Venlafaxine, 363P
Verapamil, 461
Visual analogue scale, 335

Warfarin, 375P, 429